title: Treating dry skin and pruritus with a bath oil containing soya oil and lauromacrogols.
abstract: The efficacy and safety of a bath oil containing soya oil and anti-pruritic lauromacrogols have been demonstrated in experimental and clinical studies. In order to generate more efficacy and safety-related data on the day-to-day use in paediatric practice, a post-marketing surveillance study has been conducted. More than 3500 patients--the vast majority (61.4%) aged 0-4 years--were included in this investigation. Atopic eczema was diagnosed in 86.4% of the cases. The average duration of treatment was 42 days. The results confirm that the anti-pruritic bath oil is both well-tolerated and effective in treating dry and itchy skin diseases. The sum score of symptoms decreased during the treatment period from 7.21 to 2.71 mean score points. The physicians assessed the global efficacy in 89.4% of the cases as 'very good' or 'good'. Anti-pruritic properties of the combination were rated 'very good' or 'good' in 84.3%. The local tolerability was stated to be 'good' or 'very good' in 96.8% of the patients. In total, only 10 out of the 3566 patients, 0.28% respectively, experienced discomfort.Moreover, the physicians estimated that the bath oil therapy helped to reduce therapeutics like steroids in nearly 60% of patients. The potential to reduce use of external steroids and other specific therapeutics is also of particular relevance from a pharmacoeconomic point of view.
authors.affiliation: Bonn, Germany.
authors.forename: Barbara I
authors.initials: BI
authors.lastname: Bettzuege-Pfaff
authors.forename: Antje
authors.initials: A
authors.lastname: Melzer
mesh_terms: D000293:Adolescent; D000328:Adult; D000982:Antipruritics / Q000627:therapeutic use*; D001494:Baths; D002648:Child; D002675:Child, Preschool; D003879:Dermatologic Agents / Q000627:therapeutic use; D004643:Emollients / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D011092:Polyethylene Glycols / Q000737:chemistry / Q000627:therapeutic use*; D011358:Product Surveillance, Postmarketing; D011537:Pruritus / Q000628:therapy*; D012871:Skin Diseases / Q000473:pathology / Q000628:therapy*; D013024:Soybean Oil / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000982:Antipruritics; D003879:Dermatologic Agents; D004643:Emollients; D011092:Polyethylene Glycols; D013024:Soybean Oil